GlassScriptPhysician profile
Michael Labagnara
NPI 1881094357
$28,281.13
in general payments reported to CMS, 2019-2025
13 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,526 · 2020: $3,329 · 2021: $3,475 · 2022: $1,595 · 2023: $11K · 2024: $5,353 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Food and Beverage: $594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,762.50 |
| Food and Beverage | $593.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $20,859.50 | 2021-2024 | Infinity Occipitocervical Upper Thoracic System, Cd Horizon Spinal System, Clydesdale Ptc Spinal System |
| Globus Medical, INC. | $2,715.42 | 2019-2025 | Elsa, Creo Mis Stabilization System |
| Medtronic USA, INC. | $1,764.44 | 2019-2020 | |
| Nuvasive, INC. | $1,527.77 | 2020 | |
| Zimmer Biomet Holdings, INC. | $579.41 | 2019-2021 | |
| Medicrea USA, Corp. | $196.31 | 2019 | |
| Xtant Medical INC | $163.32 | 2022 | |
| Si-Bone, INC. | $148.71 | 2019 | |
| Centinel Spine, LLC | $102.76 | 2019 | |
| Penumbra, INC. | $101.20 | 2022 | |
| Integra Lifesciences Corporation | $70.24 | 2019 | |
| Boston Scientific Corporation | $28.51 | 2019-2025 | Accolade Sr |
| Zimvie INC. | $23.54 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Labagnara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.